Swedish-Nature-25-1248x672

AAV Complement Activation Assays

Identify Complement Activation as a Result of AAV administration.

gene therapy

AAV Complement Activation Assays

AAV Complement Activation Assays

Adeno-associated virus (AAV)-based gene therapy shows great promise for treating diverse genetic disorders, but high doses have been shown to activate the complement system, risking patient safety and therapeutic efficacy.

Measuring AAV-Induced Complement Activation

Our AAV-Associated Complement Activation ELISA is a robust, highly sensitive, and serotype-specific assay designed to evaluate AAV-induced complement activation.

This 96-well ELISA platform accommodates both wild-type and novel AAV capsid variants, including engineered and chimeric forms. Its precise customization and proven sensitivity enable accurate profiling of capsid-specific immune responses, even at low antibody titers, providing valuable insight into complement activation mechanisms.

  • Customizable serotype-specific detection: Tailored to wild-type and novel AAV capsid variants for precise immune response profiling.
  • High sensitivity: Detects complement activation even at low antibody titers, reflecting real-world patient variability.
  • Mechanistic insight: Captures pathway-independent activation to reduce uncertainty in AAV immunogenicity assessment.

Our AAV Complement Activation Assays

Didn't find what you were looking for?

We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.

Contact Us

How it works

ELISA plate coated with immobilized vector

1. ELISA plate coated with immobilized vector

Wild-type vectors or your custom vector can be used.

Capture of Anti-AAV Binders

2. Capture of Anti-AAV Binders

Anti-AAV antibodies and potential complement activators (e.g., immunoglobulins/C1q, MBL/ficolins, and C3b) are captured from a human serum sample under complement-suppressing conditions.

Complement activation

3. Complement activation

Following a washing step, the serum sample is reapplied in a complement-permissive buffer. If complement-activating binders are present, terminal pathway activity results in TCC deposition.

Detection

4. Detection

Detection is performed using an anti-TCC antibody, generating a signal proportional to the level of complement activation.

Contact our gene therapy team

Write us a message and a product specialist will get in touch